Biomarkers in medicine · 2026
Serial sST2 dynamics after transcatheter tricuspid valve intervention: a candidate biomarker of biological response.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Edlinger Christoph, Schlegl Johannes, Bannehr Marwin, Lichtenauer Michael, Kücken Tanja, Krutz Alexander, Paar Vera, Neuß Michael, Haase-Fielitz Anja, Butter Christian
Аннотация
AIMS: Patients undergoing transcatheter tricuspid valve intervention (TTVI) frequently present with advanced right-sided heart failure and multiorgan dysfunction, limiting the interpretability of conventional biomarkers such as natriuretic peptides. Soluble suppression of tumorigenicity 2 (sST2), a marker of myocardial strain, inflammation, and fibrosis, may provide complementary insight into biological response following intervention.
PATIENTS & METHODS: In this prospective single-center cohort study, 135 patients undergoing TTVI were included. Plasma concentrations of sST2 were measured at baseline, discharge, 3 months, and 12 months. Longitudinal changes were analyzed using non-parametric repeated measures testing and compared with established biomarkers, including GDF-15, suPAR, H-FABP, NT-proANP and supplementary NT-proBNP analyses.
RESULTS: sST2 demonstrated a distinct biphasic trajectory, with an early increase at discharge followed by a significant decline at 3 and 12 months below baseline levels (overall p < 0.001). This pattern remained consistent in sensitivity analyses. In contrast, GDF-15, suPAR, H-FABP, NT-proANP, and supplementary NT-proBNP analyses showed heterogeneous longitudinal profiles without the sustained treatment-related trajectory observed for sST2.
CONCLUSIONS: In patients undergoing TTVI, sST2 exhibits a characteristic longitudinal profile reflecting biological response to intervention. These findings identify sST2 as a candidate dynamic biomarker and support a framework distinguishing prognostic baseline-risk biomarkers from dynamic treatment-response biomarkers.
PATIENTS & METHODS: In this prospective single-center cohort study, 135 patients undergoing TTVI were included. Plasma concentrations of sST2 were measured at baseline, discharge, 3 months, and 12 months. Longitudinal changes were analyzed using non-parametric repeated measures testing and compared with established biomarkers, including GDF-15, suPAR, H-FABP, NT-proANP and supplementary NT-proBNP analyses.
RESULTS: sST2 demonstrated a distinct biphasic trajectory, with an early increase at discharge followed by a significant decline at 3 and 12 months below baseline levels (overall p < 0.001). This pattern remained consistent in sensitivity analyses. In contrast, GDF-15, suPAR, H-FABP, NT-proANP, and supplementary NT-proBNP analyses showed heterogeneous longitudinal profiles without the sustained treatment-related trajectory observed for sST2.
CONCLUSIONS: In patients undergoing TTVI, sST2 exhibits a characteristic longitudinal profile reflecting biological response to intervention. These findings identify sST2 as a candidate dynamic biomarker and support a framework distinguishing prognostic baseline-risk biomarkers from dynamic treatment-response biomarkers.